It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
There is an ongoing need of developing sensitive and specific methods for the determination of SARS-CoV-2 seroconversion. For this purpose, we have developed a multiplexed flow cytometric bead array (C19BA) that allows the identification of IgG and IgM antibodies against three immunogenic proteins simultaneously: the spike receptor-binding domain (RBD), the spike protein subunit 1 (S1) and the nucleoprotein (N). Using different cohorts of samples collected before and after the pandemic, we show that this assay is more sensitive than ELISAs performed in our laboratory. The combination of three viral antigens allows for the interrogation of full seroconversion. Importantly, we have detected N-reactive antibodies in COVID-19-negative individuals. Here we present an immunoassay that can be easily implemented and has superior potential to detect low antibody titers compared to current gold standard serology methods.
Egia-Mendikute et al. develop a multiplexed flow cytometric bead array to simultaneously detect antibodies reactive to three immunogenic SARS-CoV-2 proteins. More sensitive than ELISA, they detected N-reactive antibodies in COVID-19-negative individuals with this assay, showing it to have superior potential to detect low antibody titres compared to current gold standard serology methods.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Basque Research and Technology Alliance (BRTA), Cancer Immunology and Immunotherapy Lab, CIC bioGUNE, Bizkaia, Spain (GRID:grid.420175.5) (ISNI:0000 0004 0639 2420)
2 Basque Research and Technology Alliance (BRTA), Precision Medicine and Metabolism Lab, CIC bioGUNE, Bizkaia, Spain (GRID:grid.420175.5) (ISNI:0000 0004 0639 2420)
3 Basque Research and Technology Alliance (BRTA), Liver Disease Laboratory, CIC bioGUNE, Bizkaia, Spain (GRID:grid.420175.5) (ISNI:0000 0004 0639 2420); Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
4 Universidad de Cantabria, Servicio Inmunología, Hospital Universitario Marqués de Valdecilla-IDIVAL, Facultad de Medicina, Cantabria, Spain (GRID:grid.7821.c) (ISNI:0000 0004 1770 272X)
5 Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427); Basque Research and Technology Alliance (BRTA), Structure and Cell Biology of Viruses Lab, CIC bioGUNE, Bizkaia, Spain (GRID:grid.420175.5) (ISNI:0000 0004 0639 2420); Ikerbasque, Basque Foundation for Science, Bizkaia, Spain (GRID:grid.424810.b) (ISNI:0000 0004 0467 2314)
6 Basque Research and Technology Alliance (BRTA), Precision Medicine and Metabolism Lab, CIC bioGUNE, Bizkaia, Spain (GRID:grid.420175.5) (ISNI:0000 0004 0639 2420); Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
7 Basque Research and Technology Alliance (BRTA), Cancer Immunology and Immunotherapy Lab, CIC bioGUNE, Bizkaia, Spain (GRID:grid.420175.5) (ISNI:0000 0004 0639 2420); Ikerbasque, Basque Foundation for Science, Bizkaia, Spain (GRID:grid.424810.b) (ISNI:0000 0004 0467 2314)